Brief: Allena Pharmaceuticals Announces Agreement With Duke Clinical Research Institute For URIROX-2 Pivotal Phase 3 Trial
27/03/2019 12:17
March 27 (Reuters) - Allena Pharmaceuticals Inc ALNA.O :
* ALLENA PHARMACEUTICALS ANNOUNCES AGREEMENT WITH DUKE
CLINICAL
RESEARCH INSTITUTE FOR URIROX-2 PIVOTAL PHASE 3 TRIAL
* ALLENA - DCRI ACC WILL ESTABLISH ACADEMIC STEERING
COMMITTEE
(ASC) TO PROVIDE INDEPENDENT OVERSIGHT AND SUPPORT INVESTIGATOR
ENGAGEMENT FOR URIROX-2.
Source text for Eikon: ID:nGNX7PMbpd
Further company coverage: ALNA.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Allena Pharmaceuticals
See all newsBrief: Allena Pharmaceuticals Inc - On September 6, Received Notice From Nasdaq That Its Shares Will Be Suspended At Open Of Business On September 8, 2022
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners
U.S. STOCKS ON THE MOVE-Timken, Bed Bath & Beyond, HyreCar, chip stocks
Allena down on bankruptcy filing